Document Detail


Treatment of sialorrhoea in patients with Parkinson's disease: best current evidence.
MedLine Citation:
PMID:  17620887     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
(1) Sialorrhoea is a common condition in patients with Parkinson's disease that has a negative impact on patient quality of life. (2) Traditionally, muscarinic antagonists have been the pharmacological agents of choice for the treatment of sialorrhoea; however, these agents are frequently associated with adverse events in patients with Parkinsonian disorders. (3) Recent studies suggest that botulinum toxin injection is currently the most effective treatment option for Parkinsonian-related sialorrhoea.
Authors:
Luke Molloy
Related Documents :
20573537 - Diffusion tensor imaging of the corpus callosum differentiates corticobasal syndrome fr...
15897497 - Does bilateral stimulation of the subthalamic nucleus aggravate apathy in parkinson's d...
8723147 - Computational analysis of open loop handwriting movements in parkinson's disease: a rap...
17620887 - Treatment of sialorrhoea in patients with parkinson's disease: best current evidence.
7211487 - Pituitary function in patients with enlarged sella turcica and primary empty sella synd...
1080557 - The sodium pertechnetate tc 99m scan: an aid in the evaluation of gastrointestinal blee...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in neurology     Volume:  20     ISSN:  1350-7540     ISO Abbreviation:  Curr. Opin. Neurol.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-07-10     Completed Date:  2007-12-27     Revised Date:  2013-01-18    
Medline Journal Info:
Nlm Unique ID:  9319162     Medline TA:  Curr Opin Neurol     Country:  England    
Other Details:
Languages:  eng     Pagination:  493-8     Citation Subset:  IM    
Affiliation:
Wolters Kluwer Health/Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Botulinum Toxins, Type A / therapeutic use
Humans
Muscarinic Antagonists / therapeutic use*
Neuromuscular Agents / therapeutic use
Parkinson Disease* / complications,  physiopathology
Quality of Life
Review Literature as Topic
Sialorrhea* / drug therapy,  etiology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Muscarinic Antagonists; 0/Neuromuscular Agents; EC 3.4.24.69/Botulinum Toxins, Type A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Medication-related impulse control and repetitive behaviors in Parkinson's disease.
Next Document:  The role of distraction osteogenesis in mandibular reconstruction.